ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Address
675 WEST KENDALL STREET
CAMBRIDGE, MA 02142
Founded
2002
Number of Employees
2,100
Website
http://www.alnylam.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | - | - | - | - | - | - | - | $738 | - | - | $738 |
| Average Price | - | - | - | - | - | - | - | - | $231.84 | - | - | $231.84 |
| # Shares Purchased | - | - | - | - | - | - | - | - | 3,182 | - | - | 3,182 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | 14.3% | - | - | 14.3% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | 37.3% | - | - | 37.3% |
| Excess Total Return | - | - | - | - | - | - | - | - | -23.0% | - | - | -23.0% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | 59% | - | - | 52% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at ALNY make a trade.
Creating a free account takes less than one minute